Figure 2.

Tumor Remission after ZIKV^BR Treatment in Boxer Dog Bearing Oligodendroglioma

(A) Representative transversal tumor MRI at days 0, 14, 21, 35, 60, 90, 120, and 150 after clinical ZIKV^BR oncolytic treatment protocol beginning. (B) Tumor volume growth kinetics quantified by MRI analysis. (C) Representative 3D MRI analyses of four different dimensions at day 0 and 60 after ZIKV^BR first injection. Scale bar, 1 cm. (D) Post-mortem macro images of CNS tumor. Scale bar, 1 cm. (E–M) Representative images of tumor (E and F), cerebellum (G), medulla (H), left testicle (I), and right testicle bearing leydigoma (J–M) tissues. IHC (E, I–K) staining for H&E and ZIKV^BR (brown, white arrowhead), and IF (F–H, L and M) Immunolabeling for ZIKV^BR (red, white arrowhead), β3-tubulin cytoplasmatic (green) protein and nuclei DAPI (blue). Scale bar, 100 μm (E, I, and K), 20 μm (F–H, L and M), and 200 μm (J).